Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more
Amoeba SA (ALMIB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.187x
Based on the latest financial reports, Amoeba SA (ALMIB) has a cash flow conversion efficiency ratio of 0.187x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.67 Million) by net assets (€-14.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amoeba SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Amoeba SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Amoeba SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoeba SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGILYX ASA NK -02
F:5NQ
|
N/A |
|
R&B FOOD SUPPLY
BK:RBF-R
|
N/A |
|
We & Win Development Co Ltd
TW:2537
|
-0.081x |
|
Aminologics Co.Ltd
KQ:074430
|
-0.074x |
|
Noroo Paint
KO:090350
|
-0.006x |
|
Columbus A/S
CO:COLUM
|
0.010x |
|
DAM CAPITAL ADVISORS LTD
NSE:DAMCAPITAL
|
N/A |
|
Skyline Bankshares Inc.
OTCQX:SLBK
|
0.047x |
Annual Cash Flow Conversion Efficiency for Amoeba SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of Amoeba SA from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-10.41 Million | €-4.22 Million | 0.405x | -75.44% |
| 2023-12-31 | €-3.94 Million | €-6.50 Million | 1.649x | +349.19% |
| 2022-12-31 | €8.16 Million | €-5.40 Million | -0.662x | +97.77% |
| 2021-12-31 | €198.68K | €-5.90 Million | -29.704x | -1727.93% |
| 2020-12-31 | €2.00 Million | €-3.25 Million | -1.625x | -89.00% |
| 2019-12-31 | €4.23 Million | €-3.64 Million | -0.860x | +12.73% |
| 2018-12-31 | €5.41K | €-5.33K | -0.985x | -142.87% |
| 2017-12-31 | €12.52K | €-5.08K | -0.406x | -32.43% |
| 2016-12-31 | €18.63K | €-5.71K | -0.306x | +22.04% |
| 2015-12-31 | €10.60K | €-4.16K | -0.393x | +7.81% |
| 2014-12-31 | €2.80 Million | €-1.19 Million | -0.426x | -136.98% |
| 2013-12-31 | €433.99K | €500.21K | 1.153x | +771.59% |
| 2012-12-31 | €947.20K | €-162.56K | -0.172x | -- |